The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06742996




Registration number
Help: Registration number
NCT06742996
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
16/12/2024
Date registered
Help: Date registered
19/12/2024
Date last updated
Help: Date last updated
29/10/2026

Titles & IDs
Public title
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Scientific title
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Additional trial identifiers [1] 0 0
2024-515593-27-00
Additional trial identifiers [2] 0 0
BGB-11417-302
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Mantle Cell Lymphoma 0 0
B Cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Sonrotoclax
Treatment: Drugs - Zanubrutinib
Treatment: Drugs - Placebo

Experimental: Arm A: sonrotoclax plus zanubrutinib - Sonrotoclax and zanubrutinib will be administered in combination.

Placebo comparator: Arm B: placebo plus zanubrutinib - Placebo and zanubrutinib will be administered in combination.


Treatment: Drugs: Sonrotoclax
Administered orally

Treatment: Drugs: Zanubrutinib
Administered orally

Treatment: Drugs: Placebo
Administered orally

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)
Timepoint [1] 0 0
Approximately 41 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Approximately 92 months
Secondary outcome [2] 0 0
PFS as assessed by investigator (INV)
Timepoint [2] 0 0
Approximately 58 months
Secondary outcome [3] 0 0
Overall Response Rate (ORR) as assessed by BIRC and by INV
Timepoint [3] 0 0
Approximately 58 months
Secondary outcome [4] 0 0
Duration of Response (DOR) as assessed by BIRC and by INV
Timepoint [4] 0 0
Approximately 58 months
Secondary outcome [5] 0 0
Complete Response Rate (CRR) as assessed by BIRC and by INV
Timepoint [5] 0 0
Approximately 58 months
Secondary outcome [6] 0 0
Time to first response as assessed by BIRC and by INV
Timepoint [6] 0 0
Approximately 58 months
Secondary outcome [7] 0 0
Time to initiation of new anticancer therapy
Timepoint [7] 0 0
Approximately 58 months
Secondary outcome [8] 0 0
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Non-Hodgkin Lymphoma High Grade Module 29 (EORTC-QLQ-NHL-HG29)
Timepoint [8] 0 0
Approximately 58 months
Secondary outcome [9] 0 0
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Timepoint [9] 0 0
Approximately 58 months
Secondary outcome [10] 0 0
Number of participants with treatment-emergent adverse events (TEAEs)
Timepoint [10] 0 0
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 58 months

Eligibility
Key inclusion criteria
* Histologically locally confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC)
* Ability to provide archival or fresh tumor tissue for retrospective central confirmation of MCL diagnosis
* Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator
* Relapsed or refractory disease after the last line of therapy
* Measurable disease defined as = 1 nodal lesion that is > 1.5 cm in longest diameter, or = 1 extranodal lesion that is > 1 cm in longest diameter
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
* Adequate organ function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
* Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i)
* Prior therapy with BTK degraders
* Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to failure of BTKi therapy are ineligible.
* Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
* Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug
* Known central nervous system involvement by lymphoma
* Clinically significant cardiovascular disease
* History of stroke or intracranial hemorrhage within 6 months before first dose of study drug

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
Sunshine Coast Hospital and Health Service - Birtinya
Recruitment hospital [2] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [3] 0 0
Monash Health - Clayton
Recruitment hospital [4] 0 0
Rockingham Hospital - Cooloongup
Recruitment hospital [5] 0 0
Perth Blood Institute - West Perth
Recruitment postcode(s) [1] 0 0
QLD 4575 - Birtinya
Recruitment postcode(s) [2] 0 0
VIC 3128 - Box Hill
Recruitment postcode(s) [3] 0 0
VIC 3168 - Clayton
Recruitment postcode(s) [4] 0 0
WA 6168 - Cooloongup
Recruitment postcode(s) [5] 0 0
WA 6005 - West Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
Argentina
State/province [27] 0 0
Caba
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad Autonoma Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Córdoba
Country [30] 0 0
Austria
State/province [30] 0 0
Sankt Pölten
Country [31] 0 0
Brazil
State/province [31] 0 0
Barretos
Country [32] 0 0
Brazil
State/province [32] 0 0
Belo Horizonte
Country [33] 0 0
Brazil
State/province [33] 0 0
Campinas
Country [34] 0 0
Brazil
State/province [34] 0 0
Caxias do Sul
Country [35] 0 0
Brazil
State/province [35] 0 0
Curitiba
Country [36] 0 0
Brazil
State/province [36] 0 0
Joinville
Country [37] 0 0
Brazil
State/province [37] 0 0
Porto AlegreRS
Country [38] 0 0
Brazil
State/province [38] 0 0
Recife
Country [39] 0 0
Brazil
State/province [39] 0 0
São Paulo
Country [40] 0 0
Brazil
State/province [40] 0 0
Vitória
Country [41] 0 0
China
State/province [41] 0 0
Beijing Municipality
Country [42] 0 0
China
State/province [42] 0 0
Chongqing Municipality
Country [43] 0 0
China
State/province [43] 0 0
Guangdong
Country [44] 0 0
China
State/province [44] 0 0
Heilongjiang
Country [45] 0 0
China
State/province [45] 0 0
Henan
Country [46] 0 0
China
State/province [46] 0 0
Hubei
Country [47] 0 0
China
State/province [47] 0 0
Jiangsu
Country [48] 0 0
China
State/province [48] 0 0
Jiangxi
Country [49] 0 0
China
State/province [49] 0 0
Liaoning
Country [50] 0 0
China
State/province [50] 0 0
Shaanxi
Country [51] 0 0
China
State/province [51] 0 0
Shandong
Country [52] 0 0
China
State/province [52] 0 0
Shanghai Municipality
Country [53] 0 0
China
State/province [53] 0 0
Sichuan
Country [54] 0 0
China
State/province [54] 0 0
Zhejiang
Country [55] 0 0
France
State/province [55] 0 0
Montpellier
Country [56] 0 0
France
State/province [56] 0 0
Nantes
Country [57] 0 0
France
State/province [57] 0 0
PierreBenite
Country [58] 0 0
France
State/province [58] 0 0
Tours
Country [59] 0 0
Germany
State/province [59] 0 0
Chemnitz
Country [60] 0 0
Germany
State/province [60] 0 0
Frankfurt am Main
Country [61] 0 0
Germany
State/province [61] 0 0
Halle
Country [62] 0 0
Germany
State/province [62] 0 0
Mutlangen
Country [63] 0 0
Germany
State/province [63] 0 0
München
Country [64] 0 0
Germany
State/province [64] 0 0
Siegen
Country [65] 0 0
Germany
State/province [65] 0 0
Stuttgart
Country [66] 0 0
Italy
State/province [66] 0 0
Bologna
Country [67] 0 0
Italy
State/province [67] 0 0
Lecce
Country [68] 0 0
Italy
State/province [68] 0 0
Meldola
Country [69] 0 0
Italy
State/province [69] 0 0
Trieste
Country [70] 0 0
Italy
State/province [70] 0 0
Verona
Country [71] 0 0
Japan
State/province [71] 0 0
Aichi-ken
Country [72] 0 0
Japan
State/province [72] 0 0
Chiba
Country [73] 0 0
Japan
State/province [73] 0 0
Ehime
Country [74] 0 0
Japan
State/province [74] 0 0
Gifu
Country [75] 0 0
Japan
State/province [75] 0 0
Hiroshima
Country [76] 0 0
Japan
State/province [76] 0 0
Hokkaido
Country [77] 0 0
Japan
State/province [77] 0 0
Hyogo
Country [78] 0 0
Japan
State/province [78] 0 0
Kagoshima-ken
Country [79] 0 0
Japan
State/province [79] 0 0
Kanagawa
Country [80] 0 0
Japan
State/province [80] 0 0
Miyagi
Country [81] 0 0
Japan
State/province [81] 0 0
Okayama-ken
Country [82] 0 0
Japan
State/province [82] 0 0
Osaka
Country [83] 0 0
Japan
State/province [83] 0 0
Saitama
Country [84] 0 0
Japan
State/province [84] 0 0
Tokyo
Country [85] 0 0
Japan
State/province [85] 0 0
Yokohama
Country [86] 0 0
New Zealand
State/province [86] 0 0
Auckland
Country [87] 0 0
New Zealand
State/province [87] 0 0
Christchurch
Country [88] 0 0
New Zealand
State/province [88] 0 0
Dunedin
Country [89] 0 0
New Zealand
State/province [89] 0 0
Tauranga
Country [90] 0 0
New Zealand
State/province [90] 0 0
Wellington
Country [91] 0 0
Poland
State/province [91] 0 0
Krakow
Country [92] 0 0
Poland
State/province [92] 0 0
Lodz
Country [93] 0 0
Poland
State/province [93] 0 0
Lublin
Country [94] 0 0
Poland
State/province [94] 0 0
Skorzewo
Country [95] 0 0
Poland
State/province [95] 0 0
Wroclaw
Country [96] 0 0
Puerto Rico
State/province [96] 0 0
San Juan
Country [97] 0 0
South Korea
State/province [97] 0 0
Busan Gwang'Yeogsi
Country [98] 0 0
South Korea
State/province [98] 0 0
Seoul Teugbyeolsi
Country [99] 0 0
Spain
State/province [99] 0 0
Barcelona
Country [100] 0 0
Spain
State/province [100] 0 0
Madrid
Country [101] 0 0
Spain
State/province [101] 0 0
Majadahonda
Country [102] 0 0
Turkey (Türkiye)
State/province [102] 0 0
Ankara
Country [103] 0 0
Turkey (Türkiye)
State/province [103] 0 0
Dokuma
Country [104] 0 0
Turkey (Türkiye)
State/province [104] 0 0
Kocaeli
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Birmingham
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Bournemouth
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Glasgow
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Headington
Country [109] 0 0
United Kingdom
State/province [109] 0 0
London
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Metropolitan Borough of Wirral
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
BeOne Medicines
Address
Country
Secondary sponsor
Nil

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
BeOne Medicines
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Director
Address 0 0
Country 0 0
Phone 0 0
1.877.828.5568
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
See plan description
Available to whom?
See plan description
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://beonemedicines.com/science/clinical-trials/


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.